Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Combination of sorafenib and capsaicin exhibited an enhanced antitumor activity in hepatocellular carcinoma and renal cell carcinoma in mice

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: GAO, Jianjun (Qingdao, China)
  • Co-author(s): Jianjun Gao: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
    Yuhao Ni: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
    Sushan Zhang: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
    Chenru Zhao: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
    Zhen Qiao: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
    Hongxia Yu: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
    Luyao Wang: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
    Jinyan Sun: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
    Chen Du: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
    Jiahao Zhang: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
    Liying Dong: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
    Ke-Wei Wang: Pharmacology, Qingdao University School of Pharmacy, Qingdao, China
  • Abstract:

    Backgrounds

    Sorafenib, a small inhibitor of tyrosine protein kinases, is currently used as a first-line drug to treat advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). Capsaicin displays antitumor activity alone and enhances the sensitivity of cancer cells to cytotoxic drugs.

    Aims

    The present study aims to investigate the

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses